FIELD: medicine.
SUBSTANCE: present invention relates to medicine, biotechnology and immunology. Disclosed is use of type I anti-CD20 antibodies for treating cancer expressing CD20, as well as use for preparing a drug for treating cancer expressing CD20, characterised by that said type I anti-CD20 antibody is introduced together with type II anti-CD20 antibody, where type I anti-CD20 antibody is rituximab, and type II anti-CD20 antibody is humanised B-LyI antibody, wherein at least 40 % or more oligosaccharides of Fc regions of type II anti-CD20 antibodies in composition are non-fucosylated, and cancer expressing CD20 is Non-Hodgkin's lymphoma.
EFFECT: use of type I anti-CD20 antibody together with type II anti-CD20 antibody under present invention provides long-term tumour growth inhibition as compared to using said antibodies separately.
4 cl, 3 dwg, 2 tbl, 3 ex
